Ligand Pharmaceuticals (NASDAQ:LGND) versus AquaBounty Technologies (NASDAQ:AQB) Head-To-Head Analysis

AquaBounty Technologies (NASDAQ:AQB – Get Free Report) and Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Profitability

This table compares AquaBounty Technologies and Ligand Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AquaBounty Technologies N/A -174.01% -43.18%
Ligand Pharmaceuticals 20.27% 5.22% 2.74%

Insider and Institutional Ownership

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares AquaBounty Technologies and Ligand Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AquaBounty Technologies $2.47 million 1.72 -$18.49 million ($0.69) -1.19
Ligand Pharmaceuticals $268.09 million 21.92 $124.45 million $2.24 131.17

Ligand Pharmaceuticals has higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for AquaBounty Technologies and Ligand Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AquaBounty Technologies 1 0 0 0 1.00
Ligand Pharmaceuticals 0 1 8 0 2.89

Ligand Pharmaceuticals has a consensus price target of $355.38, indicating a potential upside of 20.95%. Given Ligand Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than AquaBounty Technologies.

Volatility and Risk

AquaBounty Technologies has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.

Summary

Ligand Pharmaceuticals beats AquaBounty Technologies on 12 of the 13 factors compared between the two stocks.

About AquaBounty Technologies

(Get Free Report)

AquaBounty Technologies was a biotechnology company focused on developing land-based aquaculture and genetically engineered Atlantic salmon. Its best-known product, AquAdvantage Salmon, was designed to grow to market size faster than conventional farmed Atlantic salmon. The company raised salmon in recirculating aquaculture systems, which filter and reuse water. Its operations included facilities in the United States and Canada, and it developed its business around supplying salmon to the North American market.

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Receive News & Ratings for AquaBounty Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AquaBounty Technologies and related companies with MarketBeat.com's FREE daily email newsletter.